Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Health outcomes in multiple sclerosis.

Peter Flachenecker1, Peter Rieckmann

  • 1Department of Neurology and Clinical Research Group for Neuroimmunology, Julius Maximilians Universität Würzburg, Würzburg, Germany. peter.flachenecker@surfeu.de

Current Opinion in Neurology
|May 29, 2004
PubMed
Summary

Indirect costs significantly contribute to the overall economic burden of multiple sclerosis (MS). Standardizing economic modeling is crucial for accurately evaluating the cost-effectiveness of new MS therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PhysioMio: bilateral and longitudinal HD-sEMG dataset of 16 hand gestures from 48 stroke patients.

Scientific data·2026
Same author

Real-World Data on Switches of the Employment Status in People with Multiple Sclerosis: A Longitudinal Observational Study of the German MS Register.

Neuroepidemiology·2025
Same author

Guiding Multiple Sclerosis Care: An Update to the 2013 Consensus Statement from the MS in the 21st Century Steering Group.

Neurology and therapy·2025
Same author

Paediatric-onset multiple sclerosis: demographics, symptoms and disease progression.

Journal of neurology, neurosurgery, and psychiatry·2025
Same author

Age-related differences in switching highly effective disease-modifying therapy in patients with multiple sclerosis.

Journal of neurology·2025
Same author

The impact of the MS bladder check tool in raising awareness of urinary symptoms in multiple sclerosis.

Multiple sclerosis and related disorders·2025

Area of Science:

  • Health Economics
  • Medical Technology Assessment
  • Neurology

Background:

  • Economic evaluations are vital for assessing innovative medical technologies.
  • Cost and cost-effectiveness analyses are increasingly prominent in multiple sclerosis (MS) research.
  • This review focuses on cost-of-illness and cost-utility studies in MS published within the last two years.

Purpose of the Study:

  • To review recent cost-of-illness and cost-utility studies in multiple sclerosis.
  • To synthesize findings on the economic burden of MS.
  • To highlight the variability and challenges in cost-effectiveness analyses for MS treatments.

Main Methods:

  • Systematic review of published cost-of-illness studies in multiple sclerosis.
  • Systematic review of published cost-utility studies in multiple sclerosis.

Related Experiment Videos

  • Analysis of economic data, including indirect costs and cost per quality-adjusted life-year.

    • Main Results:

    • Indirect costs (sick leave, retirement, income loss) constitute nearly half of the total economic burden of MS.
    • Total costs are higher in advanced stages of the disease.
    • Cost-effectiveness of recombinant interferon-beta varied widely (Euro 28,432–US$338,738 per QALY); limited, variable data exist for glatiramer acetate and mitoxantrone.

    Conclusions:

    • Health outcome studies represent an emerging area in MS research.
    • Indirect costs are a critical component of the economic impact of MS.
    • Significant differences in cost-effectiveness study results necessitate standardization of economic modeling for evaluating new MS therapies.